Two extra years of life for 143 million

InPharma Association presented a study on the impact of pharmaceutical innovations
on the health and life expectancy of the Russian population

The Pharmaceutical Innovations Association InPharma and Columbia University Professor Frank Lichtenberg presented a new study confirming that the availability of modern innovative medicines can significantly affect the increase in the average life expectancy of the Russian population.

Frank R. Lichtenberg is a Professor of Business at Columbia University Graduate School of Business and a researcher at the National Bureau of Economic Research. He graduated with honors with a bachelor's degree in history from the University of Chicago and received a master's degree and a doctorate in economics from the University of Pennsylvania. Mr. Lichtenberg has previously taught at Harvard University and the University of Pennsylvania. He worked as an expert at the Federal Trade Commission and the U.S. Department of Justice, cooperated with State Prosecutors and spoke before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau. He was a visiting professor at the Polytechnic School in Paris and a visiting scientist at the Wissenschaftszentrum in Berlin, the University of Munich, Victoria University (Melbourne, Australia) and others.

In his research, Professor Lichtenberg proved that if new medicines received faster access to the market and were more accessible to the population, the average life expectancy in Russia could increase by 2.1 years. It is worth noting that it is the increase in life expectancy that is one of the key goals of the Government of the Russian Federation in the field of healthcare development.

Professor Lichtenberg's research demonstrates that medicines in Russia are about 15 years older than those used in the United States. Most drugs are very old even compared to countries with a similar income level. "The widespread use of new medicines will allow the population to work, attend schools and perform daily activities, as well as reduce the number of visits to doctors and reduce the time spent in hospitals," Professor Lichtenberg said.

"The study clearly and evidently demonstrates how modern medicines affect the increase in average life expectancy. The faster patients get broad access to innovative treatment methods, the more lives we will be able to save annually," summed up Vadim Kukava, Executive Director of the InPharma Association.

Portal "Eternal youth" http://vechnayamolodost.ru21.10.2013